- Advertise
- Contact Us
- Editorial Info
- Contribute
- Terms and Conditions
- Privacy Policy
- Do not sell my Personal Information
© 2021 MJH Life Sciences™ and Rheumatology Network. All rights reserved.
Clinical Updates in Psoriatic Arthritis
The Rheumatology Network psoriatic arthritis clinical focus page provides information on the latest psoriatic arthritis news, study and clinical trial findings, and clinical guideline updates. We feature expert interviews with leading physicians and investigators, articles, videos, podcasts, and breaking FDA approvals for psoriatic arthritis drugs.
Long-Term Golimumab Treatment in Patients With Psoriatic Arthritis
September 15, 2021
The efficacy evaluation of golimumab is crucial for patients with psoriatic arthritis, particularly for treating skin manifestations and psoriasis symptoms.
Diagnostic Delay Seen in Most Patients With Psoriatic Arthritis
September 14, 2021
Early diagnosis and treatment of psoriatic arthritis leads to better long-term outcomes. Despite this, most patients have significant diagnostic delays.
FDA Announces Black Box Warnings for Certain JAK Inhibitors
September 02, 2021
The move comes amid delays in FDA approvals for multiple JAK inhibitors for the treatment of rheumatic conditions.
Alexis Ogdie-Beatty, MD: UPLIFT Survey for Psoriatic Arthritis
August 11, 2021
Alexis Ogdie-Beatty, MD, discusses the UPLIFT survey and UPLIFT Innovation Challenge, the unmet needs of patients with psoriatic arthritis, and the clinical significance of the survey’s results.
Comorbidity Burden Increases 3 Years After Diagnosis With Psoriatic Arthritis, Rheumatoid Arthritis
August 10, 2021
Compared with controls, patients with psoriatic arthritis presented more often with depression at baseline and patients with rheumatoid arthritis had a higher incidence of cardiovascular comorbidity after 3 years.
Philip J Mease, MD: Efficacy of Guselkumab for Reducing Fatigue in Psoriatic Arthritis
August 04, 2021
Philip J Mease, MD, discusses his study, “Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response—results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritis.”
Q&A: Ustekinumab Versus TNF Inhibition in Psoriatic Arthritis
August 03, 2021
In this Q&A, corresponding author Josef S Smolen, MD, discussed the findings of his study determining the effectiveness of ustekinumab versus tumor necrosis factor inhibition in patients with psoriatic arthritis.
Guselkumab Significantly Improves Fatigue in Patients With Psoriatic Arthritis
July 27, 2021
Guselkumab, an interleukin-23p19-subunit inhibitor, led to clinically significant and sustained improvements in fatigue through 1 year in patients with active psoriatic arthritis.
Rheumatology Network's Spotlight: Clinical Updates in Psoriatic Arthritis July 2021
July 23, 2021
Catch up on Rheumatology Network's most recent highlights in psoriatic arthritis news.
Tofacitinib and Adalimumab Significantly Improved Pain for Patients With Psoriatic Arthritis
July 13, 2021
“This analysis provides information on when clinically meaningful improvements in pain may be expected in patients with psoriatic arthritis receiving tofacitinib or adalimumab, and how baseline pain severity may impact response to tofacitinib, which is of value in clinical practice,” stated investigators.